Integrin/C-MET targeting leverages OC’s inhibitory effects on c-MET signaling in breast and liver cancers; conjugating nanoparticles with c-MET ligands (e.g., hepatocyte growth factor mimetics) could enhance tumor-specific accumulation. This evidence concerns the gene BGLAP and neoplasm.